Effects of Jiaohong Pills and Its Prescription on Scopolamine-induced Alzheimer's Disease Mice
10.13422/j.cnki.syfjx.20231515
- VernacularTitle:椒红丸及其组方药物对东莨菪碱诱导阿尔茨海默病小鼠的影响
- Author:
Lijinchan DONG
1
;
Weiyan CAI
1
;
Li FENG
2
;
Qing YANG
1
;
Mengting LI
1
;
Yanli WANG
1
;
Hong ZHANG
1
;
Qi LI
1
;
Xiaogang WENG
1
;
Yajie WANG
1
;
Xiaoxin ZHU
1
;
Xiaoru HU
3
;
Ying CHEN
1
Author Information
1. Institute of Chinese Materia Medica， China Academy of Chinese Medical Sciences， Beijing 100700， China
2. College of Agroforestry & Medicine， The Open University of China， Beijing 100039， China
3. National Institutes for Food and Drug Control， Beijing 100050， China
- Publication Type:Journal Article
- Keywords:
Zanthoxyli Pericarpium;
Rehmanniae Radix;
Alzheimer's disease;
learning and memory;
metabolomics
- From:
Chinese Journal of Experimental Traditional Medical Formulae
2024;30(2):37-45
- CountryChina
- Language:Chinese
-
Abstract:
ObjectiveTo investigate the effects of Jiaohong pills （JHP） and its prescription， Pericarpium Zanthoxyli （PZ） and Rehmanniae Radix （RR） cognitive dysfunction in scopolamine-induced Alzheimer's disease （AD） mice and its mechanism through pharmacodynamic and metabolomics study. MethodThe animal model of AD induced by scopolamine was established and treated with PZ， RG and JHP， respectively. The effects of JHP and its formulations were investigated by open field test， water maze test， object recognition test， avoidance test， cholinergic system and oxidative stress related biochemical test. Untargeted metabolomics analysis of cerebral cortex was performed by ultra-performance liquid chromatography-Quadrupole/Orbitrap high resolution mass spectrometry （UPLC Q-Exactive Orbitrap MS）. ResultThe behavioral data showed that， compared with the model group， the discrimination indexes of the high dose of JHP， PZ and RR groups was significantly increased （P<0.05）. The staging rate of Morris water maze test in the PZ， RR， high and low dose groups of JHP was significantly increased （P<0.05， P<0.01）， the crossing numbers in the PZ， JHP high and low dose groups were significantly increased （P<0.05， P<0.01）； the number of errors in the avoidance test were significantly reduced in the PZ and high-dose JHP groups （P<0.01）， and the error latencies were significantly increased in the JHP and its prescription drug groups （P<0.01）. Compared with the model group， the activities of acetylcholinesterase in the cerebral cortex of the two doses of JHP group and the PZ group were significantly increased （P<0.05， P<0.01）， and the activity of acetylcholinesterase in the high-dose JHP group was significantly decreased （P<0.05）， and the level of acetylcholine was significantly increased （P<0.01）. At the same time， the contents of malondialdehyde in the serum of the two dose groups of JHP decreased significantly （P<0.05， P<0.01）. The results of metabolomics study of cerebral cortex showed that 149 differential metabolites were identified between the JHP group and the model group， which were involved in neurotransmitter metabolism， energy metabolism， oxidative stress and amino acid metabolism. ConclusionJHP and its prescription can antagonize scopolamine-induced cognitive dysfunction， regulate cholinergic system， and reduce oxidative stress damage. The mechanism of its therapeutic effect on AD is related to the regulation of neurotransmitter， energy， amino acid metabolism， and improvement of oxidative stress.
